These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24294538)

  • 41. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.
    Pietschmann A; Mehdipour P; Mehdipour P; Atri M; Hofmann W; Hosseini-Asl SS; Scherneck S; Mundlos S; Peters H
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):552-8. PubMed ID: 15918047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
    Antoniou AC; Pharoah PD; McMullan G; Day NE; Ponder BA; Easton D
    Genet Epidemiol; 2001 Jul; 21(1):1-18. PubMed ID: 11443730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multi-syndrome, multi-gene risk modeling for individuals with a family history of cancer with the novel R package PanelPRO.
    Lee G; Liang JW; Zhang Q; Huang T; Choirat C; Parmigiani G; Braun D
    Elife; 2021 Aug; 10():. PubMed ID: 34406119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.
    Hashemian AH; Hajizadeh E; Kazemnejad A; Atri M; Mehdipour P
    Saudi Med J; 2009 Jan; 30(1):41-4. PubMed ID: 19139771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women.
    McClain MR; Nathanson KL; Palomaki GE; Haddow JE
    Genet Med; 2005 Jan; 7(1):34-9. PubMed ID: 15654226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bayesian meta-analysis of penetrance for cancer risk.
    Ruberu TLM; Braun D; Parmigiani G; Biswas S
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
    JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frailty Models for Familial Risk with Application to Breast Cancer.
    Gorfine M; Hsu L; Parmigiani G
    J Am Stat Assoc; 2013 Dec; 108(504):1205-1215. PubMed ID: 24678132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FamEvent: An R Package for Generating and Modeling Time-to-Event Data in Family Designs.
    Choi YH; Briollais L; He W; Kopciuk K
    J Stat Softw; 2021 Mar; 97(7):. PubMed ID: 34512212
    [No Abstract]   [Full Text] [Related]  

  • 57. SEMIPARAMETRIC TRANSFORMATION MODELS WITH MULTILEVEL RANDOM EFFECTS FOR CORRELATED DISEASE ONSET IN FAMILIES.
    Liang B; Wang Y; Zeng D
    Stat Sin; 2019; 29(4):1851-1871. PubMed ID: 31579362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statistical inference on the penetrances of rare genetic mutations based on a case-family design.
    Zhang H; Olschwang S; Yu K
    Biostatistics; 2010 Jul; 11(3):519-32. PubMed ID: 20179148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Penetrance of male breast cancer susceptibility genes: a systematic review.
    Chamseddine RS; Wang C; Yin K; Wang J; Singh P; Zhou J; Robson ME; Braun D; Hughes KS
    Breast Cancer Res Treat; 2022 Jan; 191(1):31-38. PubMed ID: 34642874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.